Requests for quotation
SciencePharma is looking for a business partner to cooperate in drug product development - PALIPERIDON, prolonged-release tablets containing 3 mg, 6 mg and 9 mg of active substance, respectively. The active substance is one of the advanced compounds used in clinical practice for schizophrenia treatment. During the project, the pharmaceutical formulation has been developed, confirming prolonged-release of the active substance in a manner comparable to INVEGA (Jansen-Cilag) reference product. The remaining essential step towards successful project finalization is to conduct the bioequivalence studies with the reference medicinal product. The final results of the project is the granting of marketing authorization in EU, developed prolonged-release tablets technology containing the mentioned paliperidone strengths along with full registration dossier.
If you are interested in the offer, please e-mail us at paliperidon|sciencepharma.pl| |paliperidon|sciencepharma.pl